It’s hard to explain Moderna’s stock’s year without a moment of introspection. Shares were trading close to $33 at the beginning of 2026. The price was almost eight times higher by the first week of November, at about $258. For a large-cap biotech, that is a big step. It is the type of move that, frequently simultaneously, evokes a particular mix of caution and excitement.
The most recent increase occurred on November 4, when shares closed at $258.38 after rising 13% in a single session. The WHO advisory group’s recommendation that Moderna’s Ebola vaccine candidate, mRNA-1469, be included in an ongoing Phase 2/3 trial in the Democratic Republic of the Congo and the company’s announcement that it would present preliminary data on its investigational mRNA therapy for multiple myeloma at a major oncology conference served as the catalysts. A commercial product was not confirmed by either development. However, both were important in a market that has been prepared to pay for pipeline potential.
The Ebola candidate is not the main focus of the 2026 rally. It’s intismeran, the customized cancer vaccine that Moderna and Merck have been working on. The partners declared in August that the trial had achieved its main goal. According to comprehensive findings published in October, patients treated for melanoma following surgery had a 42% lower relative risk of recurrence or death when intismeran was added to Merck’s Keytruda. That figure has clinical significance and is the kind of information that can change the way the market views a business. The question of whether it results in a timely regulatory submission and eventual sales is different and more difficult to answer at this time.
Analysts predicted a loss of between $1.10 and $1.25 per share going into Friday’s Q3 earnings report, with revenue expected to drop by about 13% annually. Although the decline is better than the 45% drop the company reported in the same quarter last year, those are not optimistic expectations. Moderna’s primary vaccine business, which includes COVID, flu, and RSV, is erratic and seasonal, and the company has been spending a lot of money on a pipeline that it thinks will eventually make the investment worthwhile. As 2027 approaches, investors will want to see how that balance appears.
The valuation of the stock is what is actually complicated at the moment. MRNA is currently trading at about 45 times sales. By almost all standards, that is a costly multiple. The average analyst price target is between $138 and $140, which is more than 40% less than the stock’s price on the eve of earnings. A hold is the consensus rating. Although the difference between the current price and the analysts’ targets does not necessarily indicate that the analysts are correct, it does indicate that the market has outpaced the fundamentals, at least temporarily.
A put-to-call ratio of about 1.38 for contracts expiring soon after the report was displayed by options markets prior to earnings, indicating a distinct bearish lean. Traders were pricing in a possible post-earnings decline of more than 11%, according to the lower bound on those options contracts. That doesn’t guaranty a drop, though. Moderna has a history of exceeding revenue projections, and the business hardly ever falls short. However, if management is cautious or there is any softness in the demand for seasonal vaccines, even a strong quarter may not be sufficient.
It’s difficult to ignore the situation’s irony. In 2022 and 2023, Moderna’s stock price plummeted along with its COVID vaccine revenue. Investor confidence has now been restored around a pipeline that is truly promising; the question is not whether the science is true, but rather whether the price already reflects it. Even for investors who are not particularly inclined to follow biotech closely, MRNA stock is worth keeping an eye on because of this tension.
